In April 2009, the novel influenza A (H1N1) 2009 virus had its primary outbreak in Mexico and spread throughout the world within weeks. 1 The severity of the illness seems comparable to seasonal influenza, even though the virus appears to cause higher rates of lower respiratory tract infections leading to acute respiratory distress syndrome and mechanical ventilation. 2 Immunocompromised patients are at especially high risk for complications and mortality from this infection. 3 We report on a 45-year-old Caucasian woman suffering from therapy-related myelodysplastic syndrome acquired 3 years after primary treatment for cytogenetically high-risk chronic B-cell lymphatic leukemia consolidated by auto-SCT. The patient was admitted to our center for allo-SCT from her matched sibling donor. Reduced-intensity conditioning therapy consisted of fludarabine 30 mg/m 2 once daily i.v. for 5 consecutive days (day À6 to À2) and melphalan 150 mg/m 2 once daily i.v. on day À2 commenced during induction chemotherapy-induced aplasia. 4 Except for a short period of streptococcal bacteremia-induced fever, which resolved within 2 days after specific antibiotic therapy, induction and conditioning therapy was well tolerated.
At 2 days after initiation of G-CSF stimulation, the sibling donor rapidly developed flu-like symptoms with arthralgia, headache and malaise but not fever, probably related to the intake of paracetamol. Physical examination of the donor did not reveal any infectious foci, but laboratory values showed a slight increase in C-reactive protein. As the H1N1 pandemic had spread to Austria, a nasopharyngeal swab was collected using the Copan eSwab transport system (COPAN Italia SpA, Brescia, Italy) according to the manufacturer's instructions. Influenza RNA was extracted and amplified using the Influenza A/H1N1 Detection Set (Roche Diagnostics GmbH, Mannheim, Germany). The result was positive.
As the conditioning therapy was already completed and no alternative donor was available, the donor was treated with oseltamivir 75 mg twice daily for 2 days until completion of stem-cell harvest, which yielded a total amount of 304.2 Â 10 6 CD34 þ PBSCs during a single apheresis procedure. In order to prevent viral transmission by the stem-cell graft or overt H1N1 2009 virus infection transmitted by repetitive donor-recipient contacts, the patient was treated with oseltamivir 75 mg twice daily for 10 days starting 1 day before stem-cell graft infusion. SCT was performed without any complications, with a total of 5.07 Â 10 6 CD34 þ PBSCs/kg. The post-transplant period was uneventful without fever or any other sign of infectious complications. At 3 days after leucocyte recovery, histologically confirmed acute skin GVHD (stage 2, overall grade I) occurred, but it resolved after several days of local steroid therapy. In nasopharyngeal swabs that were frequently collected, H1N1 2009 viral RNA was never detected. The time for neutrophil and plt engraftment was 16 and 11 days, respectively. A BM biopsy performed on day 27 showed normal cellularity, proportion and maturation of hematopoietic cells without any residual disease.
The influenza virus replicates within epithelial cells of the respiratory tract. Lymphopenia is the major risk factor for developing lower respiratory tract infection and for the mortality attributable to H1N1. 5 In a single-center review of 12 influenza seasons, 29% of the patients developed pneumonia with a mortality of 28%. It remains controversial whether viremia occurs during influenza infection. Viremia has been previously reported in influenza virus infection; however, several studies failed to detect viremia after the onset of illness, suggesting that influenza viremia is rare after the onset of symptoms, is not sustained for long periods and viral concentrations seem to be very low. 6 In hematopoietic SCT, early treatment with oseltamivir was shown to successfully prevent the development of pneumonia. 7 Observational studies indicated that the H1N1 2009 virus is susceptible to neuraminidase inhibitors and treatment of hospitalized patients with oseltamivir may thus reduce disease severity and mortality. 8 In this patient, prophylactic treatment with oseltamivir was given for 10 days, in therapeutic doses because of the severity of immunosuppression, in order to prevent donor-recipient transmission of infection. During close follow-up, in repetitively collected nasopharyngeal swabs, viral RNA of H1N1 2009 virus could not be detected. A further concern was the influence of oseltamivir on engraftment, which is currently unknown; cases of pronounced thrombocytopenia associated with oseltamivir administration have been described recently; 9 however, in our allo-SCT recipient, the median time for neutrophil and plt recovery was 16 and 11 days, respectively, which is comparable to that in other allogeneic peripheral stem cell transplant recipients, suggesting no detrimental effect of neuraminidase-inhibitor therapy on engraftment. mobilization or engraftment. It may be used for preventing H1N1 2009 virus transmission through the hematopoietic stem-cell graft.
